Bacteriologic and epidemiologic characteristics of Enterobacter hafniae and Enterobacter liquefaciens.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D002228:Carbenicillin / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002701:Chloramphenicol / Q000627:therapeutic use; D004755:Enterobacteriaceae / Q000302:isolation & purification*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009268:Nalidixic Acid / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology*
D002511:Cephalosporins; D005839:Gentamicins; D011113:Polymyxins; D009268:Nalidixic Acid; D007612:Kanamycin; D002701:Chloramphenicol; D000667:Ampicillin; D002228:Carbenicillin